NEW YORK (GenomeWeb News) – On-Q-ity today said that Laboratory Corporation of America will market the firm's circulating tumor cell platform to researchers in the biopharma industry.
According to the Waltham, Mass.-based firm, the technology will enable researchers to better stratify patients for potential inclusion or exclusion in clinical trials; more quickly identify patients eligible for study enrollment; better monitor cancer response to treatment; and use CTCs as an earlier indicator of treatment effectiveness.
"On-Q-ity’s CTC platform will provide researchers with a cost-effective, easy-to-use, and extremely accurate test to find and characterize tumor cells circulating in a patient’s blood," On-Q-ity CEO Mara Aspinall said in a statement.
Terms of the alliance were not disclosed.
On-Q-ity is one of several firms developing assays based on circulating tumor cells. Among the others are Advanced Cell Diagnostics and Biocept. Johnson & Johnson company Veridex already markets a circulating tumor cell test called the CellSearch system.